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Detection and Clinical Consequences*Cindy L. Grines, MD, Theodore L. Schreiber, MDI t is well known that vulnerable plaque is charac-terized by a thin cap with underlying soft ather-omatous material that may rupture causing
acute myocardial infarction. What is less well known
is how to identify vulnerable plaque and how it
should be treated to reduce major adverse cardiac
events. The color yellow, observed at the time of
atherectomy, autopsy, with near-infrared spectros-
copy, or with angioscopy, has been associated with
extensive atheroma that may be more likely to cause
cardiac events. Moreover, angioscopy is helpful in
visualizing soft, ulcerated plaques as well as distin-
guishing between red and white thrombus.SEE PAGE 814In this issue of JACC: Cardiovascular Interventions,
angioscopy was used to determine in-stent neo-
atherosclerosis after drug-eluting stents (DES). In a
series of 360 patients with angioscopy 1 year after
DES, Ueda et al. (1) found that the presence of yellow
plaque was predictive of major adverse cardiac events
at long-term follow-up. Yellow “neoatherosclerosis”
was independently predictive of late events (hazard
ratio: 5.38), along with small stent size and absence
of statin (only 74% of patients were on a statin at
1 year). Unexpectedly, neointimal coverage and
presence of thrombus were not predictive of late
events. One may think of yellow atheroma as a
vulnerable plaque, especially when associated with
more thrombus as in this study; however, it was not
associated with risk of unstable angina or myocardial*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
From the Department of Cardiology, Detroit Medical Center Heart Hos-
pital, and Wayne State University, Detroit, Michigan. Both authors have
reported that they have no relationships relevant to the contents of this
paper to disclose.infarction. Target lesion revascularization was largely
responsible for the increased cardiac event rate.
Although neoatherosclerosis has been implicated in
late restenosis in other studies, these investigators
did not report baseline atheromatous burden at the
time of stenting, or minimal lumen diameter at 1 year
(both are strong predictors of restenosis). Thus, one
does not know whether the yellow color was due to
“neo” or pre-existing atherosclerosis, and how much
of the restenosis was due to neointimal proliferation
already present at 1 year.
What is the difference between neoatherosclerosis
and progression of existing disease? How can we
detect it? Can we prevent it? Why does it matter? The
term neoatherosclerosis was coined from imaging,
atherectomy, and autopsy studies performed after
DES. As opposed to natural atherosclerosis, which
may take several decades to develop, autopsy and
directional atherectomy specimens obtained from
inside DES indicate that additional cholesterol depo-
sition may occur within a few months, and neo-
atherosclerosis may be present in the majority of
lesions with DES restenosis (2,3). We were not sur-
prised by this, knowing that denuded endothelium in
the presence of high circulating cholesterol was used
as a mechanism to rapidly induce atherosclerosis
in animals. What is surprising is that early neo-
atherosclerosis does not occur with bare-metal stents
(BMS); smooth muscle cell proliferation is the primary
mechanism of BMS restenosis. Serial angiographic
and ultrasound studies have shown that BMS have
early neointimal thickening, but after 1 year, there
may be improvement in lumen size. Unfortunately,
BMS may have late (>4 years) development of neo-
atherosclerosis contributing to late stent failure (4).
Conversely, DES have less restenosis within the ﬁrst
several months but later have more loss of lumen area
and late target vessel revascularization (TVR). This
“late catch-up,” attributed to neoatherosclerosis, was
originally thought to be due to inﬂammation from
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823early DES polymers. However, neoatherosclerosis has
also been observed in second-generation stents with
thinner struts and different polymers.
When we ﬁrst heard about neoatherosclerosis, we
were not concerned. After all, it remains indisputable
that DES have sustained beneﬁt at reducing TVR,
and second-generation DES may actually have lower
rates of stent thrombosis (ST) than BMS. Although
neoatherosclerosis has been implicated in both late
restenosis and late ST, these events occur far more
frequently with paclitaxel- compared with sirolimus-
eluting stents, despite TAXUS stents having less
neoatherosclerosis (3). The mechanism of late ST
is multifactorial, and it remains uncertain whether
neoatherosclerosis contributes to late ST. There may
be more compelling evidence of its contribution
to late progression of disease requiring TVR (5–7).
Moreover, when TVR is performed in the setting of
neoatherosclerosis, the risk of periprocedural myo-
cardial infarction may be increased (8).
Thus, detection of neoatherosclerosis may be use-
ful to stratify lesions that may have higher complica-
tion rates with percutaneous coronary interventions.
It appears that optical coherence tomography is most
commonly used to detect neoatherosclerosis, consist-
ing of signal-poor regions with diffuse borders, which
may also have thin caps, neointimal rupture, and
thrombi. One study found that 68% of DES with
restenosis had neoatherosclerosis by optical coher-
ence tomography (8). This study also found that near-
infrared spectroscopy was able to detect smaller
pools of lipid within the stented vessel. Althoughintravascular ultrasound virtual histology may be
helpful with imaging de novo vulnerable plaques, its
ability to accurately analyze in-stent tissue may be
limited as a result of stent artifact.
It remains uncertain whether and how one can
prevent neoatherosclerosis of DES. Use of drug-
eluting balloons or bioabsorbable scaffolds will
likely have a different healing response to injury,
thus may not result in neoatherosclerosis. The use of
high-dose statins before percutaneous coronary in-
terventions has been shown to reduce periprocedural
myocardial infarction and renal failure, but no clear
reduction in restenosis of BMS (possibly due to lack
of early neoatherosclerosis in BMS). Interestingly, the
potential role of statins is raised by studies showing
regression of non-stented disease with high-dose
statins (9). Moreover, progression of disease in non-
target lesion areas (presumably due to natural
atherosclerosis) has been associated with in-stent
neoatherosclerosis (6). Anti-inﬂammatory medica-
tions such as prednisone, celecoxib, and colchi-
cine have shown some effect in small randomized
trials of BMS. Likewise, small trials, mostly in BMS
patients, have suggested that medications such as
cilostazol, pioglitazone, or rosiglitazone may reduce
restenosis. Whether these medications may affect
neoatherosclerosis of DES is unknown.
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